Practices


No new trial for Janssen Pharmaceutical in $2.5 million Risperdal case

August 30, 2017 - The company was seeking a new trial as part of an effort to overturn a $2.5 million jury verdict that was awarded in 2015 to an Alabama man Austin Pledger. Read More


Navan Ward appointed to Plaintiffs Executive Committee for PPI litigation

August 25, 2017 - Proton Pump Inhibitor (PPI) drugs have been linked to kidney damage. Read More


Concern over Invokana adverse side effects continues to grow

August 25, 2017 - Reports of amputations connected to canagliflozin, the key ingredient in brand name medications Invokana and Invokamet, continue to underscore the drug’s dangers. Read More


New warning labels were evidence in $417 million talc-ovarian cancer win

August 23, 2017 - Other talcum powder products now warn women about the danger of genital use. Johnson & Johnson has declined to provide similar warnings on its Johnson’s Baby Powder, which contains talc... Read More


Los Angeles jury links talc to ovarian cancer, awarding woman $417 million

August 21, 2017 - A Los Angeles jury awarded plaintiff Eva Echeverria $417 million, finding Johnson & Johnson talcum powder products responsible for her ovarian cancer. Read More


Proton Pump Inhibitor (PPI) MDL granted

August 4, 2017 - Plaintiffs are suing PPI manufacturers after developing kidney damage linked to the use of PPIs. Studies dating back to the 1990s have linked PPIs, including Nexium, Prevacid, and Prilosec,... Read More


Rare ruling in Taxotere MDL allows claims against generics

August 2, 2017 - A recent, rare ruling by the U.S. Judicial Panel on Multidistrict Litigation (JPML) allows claims against manufacturers of generic versions of Taxotere to be included in the MDL. Read More


Recent studies confirm Xarelto bleeding risks, adverse events

July 27, 2017 - There were 21,996 severe injuries reported involving anticoagulant drugs including 3,018 reported deaths, and Xarelto was the top culprit for this class of drugs. Read More


Jury hits testosterone therapy maker AbbVie with $150 million in punitive damages

July 24, 2017 - The jury found that AbbVie fraudulently marketed AndroGel by creating a condition dubbed “Low T,” presenting the product directly to men as a kind of fountain of youth. Read More


Risperdal legal troubles continue to mount

July 13, 2017 - The suit was filed by a number of child advocacy organizations on behalf of children in the Missouri foster care system who were “inappropriately provid[ed] psychotropic drugs” with... Read More


back to top